Physician profile
Catherine A Anderson
NPI 1801884317
$1,083.89
in general payments reported to CMS, 2019-2025
13 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.82 · 2022: $166 · 2023: $476 · 2024: $261 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $274.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $238.42 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $154.00 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $123.90 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $52.15 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $50.89 | 2022-2025 | Aristada, Lybalvi |
| Sobi, INC | $44.12 | 2022-2025 | |
| Tris Pharma INC | $43.10 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $31.99 | 2024 | Cobenfy |
| Lundbeck LLC | $24.02 | 2023 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $17.69 | 2023 | Austedo Xr |
| Indivior INC. | $14.82 | 2021 | |
| Neurocrine Biosciences, INC. | $14.17 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.